Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14703252 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2NPSR1P2RX7ALDH1A1EPHX2 | |
| SCHEMBL14703476 | 0.87 | KIF11 (0.40) | P2RX7MEN1KMT2AKCNH2 | |
| SCHEMBL14703147 | 0.87 | EPHX2 (0.47) | SMN1; SMN2ALDH1A1EPHX2MEN1KMT2A | |
| SCHEMBL14703474 | 0.86 | PTPN7 (0.46) | P2RX7 | |
| SCHEMBL14703141 | 0.85 | EPHX2 (0.48) | SMN1; SMN2ALDH1A1EPHX2MEN1KMT2A | |
| SCHEMBL14703368 | 0.84 | SCN3A (0.39) | SMN1; SMN2ALDH1A1EPHX2KCNH2 | |
| SCHEMBL14703143 | 0.82 | KDM4E (0.46) | ALDH1A1MEN1KMT2AHRH3KCNH2 | |
| SCHEMBL14703466 | 0.80 | KCNH2 (0.45) | P2RX7ALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL14703426 | 0.80 | MEN1 (0.52) | ALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL14703140 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2742020-B1 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | IMMUNOMET THERAPEUTICS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321742-B2 | N1-cyclic amine-N5-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same | IMMUNOMET THERAPEUTICS INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| WO-2013022279-A2 | N1-CYCLIC AMINE-N5-SUBSTITUTED BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179661-A1 | N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same | PRKAG1, GCKR, GPR119 | PHGDH 1125/4885SMN1; SMN2 3229/4885NPSR1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.